We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Hologic

Designs and provides products for clinical laboratory and blood screening, including testing items for detection of h... read more Featured Products: More products

Download Mobile App





Hologic Awarded USD 7.6 Million by HHS and DOD to Ramp Up Capacity for COVID-19 Tests

By LabMedica International staff writers
Posted on 06 Aug 2020
Print article
Illustration
Illustration
The US Department of Health & Human Services (HHS Washington, D.C., USA) and Department of Defense (DOD Arlington, VA, USA) have awarded an undefinitized contract action with a ceiling of USD 7.6 million to Hologic, Inc. (Marlborough, MA, USA) to expand production of custom sample collection and processing consumables for COVID-19 testing.

The unprecedented demand for molecular diagnostic testing driven by the COVID-19 pandemic had exceeded Hologic’s production capacity for sample collection and processing consumables. The company is well-positioned to support the demand for COVID-19 testing in the US due to the installed base of more than 1,100 fully automated, high throughput Panther and Panther Fusion systems. These Panther systems are each capable of performing more than 1,000 tests in a 24-hour period. The tube, cap, and multi-tube unit consumables are critical for performing molecular diagnostic tests on the Panther and Panther Fusion systems.

Hologic has received ongoing support to develop the COVID-19 test for these systems from the Biomedical Advanced Research and Development Authority, part of the HHS Office of the Assistant Secretary for Preparedness and Response. The latest investment will increase Hologic's production from 4.8 million COVID-19 tests per month to 6.8 million tests per month. The company is expected to deliver the increased volume of consumables to market by January 2021.

“The Trump Administration’s coordination across the Federal government is important toward the successful execution of our national testing strategy to fight COVID-19,” said HHS Assistant Secretary for Health ADM Brett Giroir, M.D. “Hologic’s platform is in high demand, and with this investment, we will be able to improve the supply to laboratories across the country.”



Print article

Channels

Immunology

view channel
Image: An enzyme-linked immunosorbent assay for mannose-binding lectin found that this molecule is associated with coagulopathy in severe COVID-19 patients (Photo courtesy of Getty Images).

Mannose-Binding Lectin Associated with Coagulopathy in Severe COVID-19

The ongoing COVID-19 pandemic has caused significant morbidity and mortality worldwide, as well as profound effects on society. COVID-19 patients have an increased risk of thromboembolic (TE) complications,... Read more

Industry News

view channel
Illustration

2020 AACC Annual Scientific Meeting & Clinical Lab Expo to Be an All Virtual Event Due to Coronavirus Pandemic

The American Association for Clinical Chemistry (AACC Washington, DC, USA) has decided to hold the 2020 AACC Annual Scientific Meeting & Clinical Lab Expo as a virtual event, rather than as a live... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.